CN113905763A - 肿瘤选择性组合治疗 - Google Patents

肿瘤选择性组合治疗 Download PDF

Info

Publication number
CN113905763A
CN113905763A CN202080037114.7A CN202080037114A CN113905763A CN 113905763 A CN113905763 A CN 113905763A CN 202080037114 A CN202080037114 A CN 202080037114A CN 113905763 A CN113905763 A CN 113905763A
Authority
CN
China
Prior art keywords
tumor
cells
nqo1
lap
dnq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080037114.7A
Other languages
English (en)
Chinese (zh)
Inventor
傅阳新
黄秀梅
大卫·布特曼
保罗·J·赫根勒特尔
李晓光
蒋令翔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
University of Texas System
University of Illinois System
Original Assignee
Indiana University Research and Technology Corp
University of Texas System
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp, University of Texas System, University of Illinois System filed Critical Indiana University Research and Technology Corp
Publication of CN113905763A publication Critical patent/CN113905763A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080037114.7A 2019-03-18 2020-03-18 肿瘤选择性组合治疗 Pending CN113905763A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819870P 2019-03-18 2019-03-18
US62/819,870 2019-03-18
PCT/US2020/023250 WO2020190990A1 (en) 2019-03-18 2020-03-18 Tumor-selective combination therapy

Publications (1)

Publication Number Publication Date
CN113905763A true CN113905763A (zh) 2022-01-07

Family

ID=72519160

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080037114.7A Pending CN113905763A (zh) 2019-03-18 2020-03-18 肿瘤选择性组合治疗

Country Status (10)

Country Link
US (1) US20220160703A1 (https=)
EP (1) EP3942061A4 (https=)
JP (1) JP2022525476A (https=)
KR (1) KR20220004025A (https=)
CN (1) CN113905763A (https=)
AU (1) AU2020240035A1 (https=)
BR (1) BR112021018545A2 (https=)
CA (1) CA3130513A1 (https=)
MX (1) MX2021011301A (https=)
WO (1) WO2020190990A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658809A (zh) * 2013-04-09 2016-06-08 伊利诺伊大学董事会 肿瘤选择性联合疗法
WO2017025496A1 (en) * 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
WO2017165732A1 (en) * 2016-03-24 2017-09-28 Tragara Pharmaceuticals, Inc. Treatment of cancer with tg02
WO2019018757A1 (en) * 2017-07-21 2019-01-24 Genentech, Inc. THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2619331T (pt) * 2010-09-22 2018-06-01 Univ Texas Métodos de tratamento de cancro incluindo rastreio de nqo1

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658809A (zh) * 2013-04-09 2016-06-08 伊利诺伊大学董事会 肿瘤选择性联合疗法
WO2017025496A1 (en) * 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
WO2017165732A1 (en) * 2016-03-24 2017-09-28 Tragara Pharmaceuticals, Inc. Treatment of cancer with tg02
WO2019018757A1 (en) * 2017-07-21 2019-01-24 Genentech, Inc. THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER

Also Published As

Publication number Publication date
BR112021018545A2 (pt) 2021-12-14
EP3942061A1 (en) 2022-01-26
CA3130513A1 (en) 2020-09-24
JP2022525476A (ja) 2022-05-16
MX2021011301A (es) 2022-01-19
EP3942061A4 (en) 2022-12-14
WO2020190990A1 (en) 2020-09-24
AU2020240035A1 (en) 2021-10-07
US20220160703A1 (en) 2022-05-26
KR20220004025A (ko) 2022-01-11

Similar Documents

Publication Publication Date Title
KR102940867B1 (ko) 다이아실글리세롤 키나제 조절 화합물
Zhang et al. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies
JP6719620B2 (ja) 腫瘍選択的併用療法
CA2986441A1 (en) Combination therapy of transcription inhibitors and kinase inhibitors
EP3755324B1 (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
CA3144985A1 (en) Hdac6-activated macrophages, compositions, and uses thereof
JP7028765B2 (ja) ベンズアミドおよび活性化合物組成物および使用方法
AU2018352382B2 (en) Compounds and methods for treating cancer
JP2018520117A (ja) Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ
WO2014082085A1 (en) Use of itk inhibitors for the treatment of cancer
CN113905763A (zh) 肿瘤选择性组合治疗
CN110891944A (zh) 用于治疗癌症的化合物、组合物及其用途
US20240293430A1 (en) Withaferin a and immune checkpoint blocker combination therapies
US20240100021A1 (en) Combination Therapy Schedules to Treat Cancer
EP4419209A1 (en) Combination decitabine and mps1 inhibitor therapy to prime cancer immunogenicity
EA048235B1 (ru) Соединения, модулирующие диацилглицеринкиназу
JP2022023033A (ja) ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
Zhang et al. CAFs-Promoted LncRNA DNM3OS Conferred Radioresistance by Regulating DNA Damage Response in a TNFSF4-Dependent Manner in Esophageal Squamous Cell Carcinoma
WO2019213499A1 (en) Compounds and methods targeting gper for treatment of diseases associated with calcium
HK40031775A (en) Compounds and methods for treating cancer
HK40031775B (en) Compounds and methods for treating cancer
HK40043674A (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
HK40043674B (en) Benzotriazole derivative for use in treating double and triple hit diffuse large b cell lymphoma
HK40080334A (en) Benzamide and active compound compositions and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220107